-DOCSTART-	
	
Whether	O
human	B-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hiPSCs	I-Material
)	I-Material
are	O
epigenetically	B-Process
identical	O
to	O
human	B-Material
embryonic	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hESCs	I-Material
)	I-Material
has	O
been	O
debated	O
in	O
the	B-Process
stem	I-Process
cell	I-Process
field	I-Process
.	O
	
In	O
this	O
study	O
,	O
we	O
analyzed	B-Process
DNA	B-Data
methylation	I-Data
patterns	I-Data
in	O
a	O
large	O
number	O
of	O
hiPSCs	B-Material
(	O
n	B-Data
=	I-Data
114	I-Data
)	O
and	O
hESCs	B-Material
(	O
n	B-Data
=	I-Data
155	I-Data
)	O
,	O
and	O
identified	B-Process
a	B-Material
panel	I-Material
of	O
82	B-Data
CpG	B-Material
methylation	I-Material
sites	I-Material
that	O
can	O
distinguish	B-Process
hiPSCs	B-Material
from	O
hESCs	B-Material
with	O
high	B-Data
accuracy	I-Data
.	O
	
We	O
show	O
that	O
12	B-Data
out	I-Data
of	I-Data
the	I-Data
82	I-Data
CpG	B-Material
sites	I-Material
were	O
subject	O
to	O
hypermethylation	B-Process
in	O
part	O
by	O
	
DNMT3B.	B-Material
Notably	O
,	O
DNMT3B	B-Material
contributes	O
directly	O
to	O
aberrant	B-Process
hypermethylation	I-Process
and	O
silencing	B-Process
of	O
the	B-Material
signature	I-Material
gene	I-Material
,	I-Material
	
TCERG1L.	I-Material
Overall	O
,	O
we	O
conclude	O
that	O
DNMT3B	B-Material
is	O
involved	O
in	O
a	B-Process
wave	I-Process
of	I-Process
de	I-Process
novo	I-Process
methylation	I-Process
during	O
reprogramming	B-Process
,	O
a	O
portion	O
of	O
which	O
contributes	O
to	O
the	B-Data
unique	I-Data
hiPSC	I-Data
methylation	I-Data
signature	I-Data
.	O
	
These	O
82	B-Data
CpG	B-Material
methylation	I-Material
sites	I-Material
may	O
be	O
useful	O
as	O
biomarkers	B-Material
to	O
distinguish	B-Process
between	O
hiPSCs	B-Material
and	O
hESCs	B-Material
.	O
	
Highlights	O
•	O
	
Eighty	B-Data
-	I-Data
two	I-Data
DNA	B-Material
methylation	I-Material
sites	I-Material
distinguish	B-Process
hiPSCs	B-Material
and	O
hESCs	B-Material
with	O
high	B-Data
accuracy	I-Data
•	O
	
Twelve	B-Data
aberrantly	B-Material
hypermethylated	I-Material
signature	I-Material
CG	I-Material
sites	I-Material
are	O
due	O
in	O
part	O
to	O
DNMT3B	B-Material
•	O
DNMT3B	B-Material
also	O
contributes	O
to	O
previously	O
reported	O
aberrant	B-Process
hypermethylation	I-Process
in	O
hiPSCs	B-Material
	
Huang	O
et	O
al	O
.	O
identify	O
a	B-Material
panel	I-Material
of	O
82	B-Data
CpG	B-Material
methylation	I-Material
sites	I-Material
that	O
can	O
robustly	O
distinguish	B-Process
hiPSCs	B-Material
from	O
hESCs	B-Material
with	O
high	B-Data
accuracy	I-Data
.	O
	
Part	O
of	O
the	B-Data
signature	I-Data
consists	O
of	O
aberrantly	B-Material
hypermethylated	I-Material
CpG	I-Material
sites	I-Material
,	O
which	O
are	O
partially	B-Process
abrogated	I-Process
in	O
the	O
absence	O
of	O
DNMT3B.	B-Material
	
In	O
addition	O
,	O
DNMT3B	B-Material
-	I-Material
mutant	I-Material
hiPSCs	I-Material
do	O
not	O
exhibit	O
other	B-Data
aberrant	I-Data
hypermethylation	I-Data
signatures	I-Data
as	O
previously	O
reported	O
.	O
	
-DOCSTART-	
	
The	B-Process
transfer	I-Process
of	O
a	B-Process
laboratory	I-Process
process	I-Process
into	O
a	B-Material
manufacturing	I-Material
facility	I-Material
is	O
one	O
of	O
the	O
most	O
critical	O
steps	O
required	O
for	O
the	B-Process
large	I-Process
scale	I-Process
production	I-Process
of	O
cell	B-Material
-	I-Material
based	I-Material
therapy	I-Material
products	I-Material
.	O
	
This	O
study	O
describes	O
the	B-Method
first	I-Method
published	I-Method
protocol	I-Method
for	O
scalable	B-Process
automated	I-Process
expansion	I-Process
of	O
human	B-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cell	I-Material
lines	I-Material
growing	B-Process
in	O
aggregates	B-Material
in	O
feeder	B-Material
-	I-Material
free	I-Material
and	I-Material
chemically	I-Material
defined	I-Material
medium	I-Material
.	O
	
Cells	B-Material
were	O
successfully	O
transferred	B-Process
between	O
different	B-Material
sites	I-Material
representative	O
of	O
research	B-Data
and	I-Data
manufacturing	I-Data
settings	I-Data
;	O
and	O
passaged	B-Process
manually	I-Process
and	O
using	O
the	B-Material
CompacT	I-Material
SelecT	I-Material
automation	I-Material
platform	I-Material
.	O
	
Modified	B-Process
protocols	I-Process
were	O
developed	O
for	O
the	B-Material
automated	I-Material
system	I-Material
and	O
the	B-Process
management	I-Process
of	O
cells	B-Material
aggregates	I-Material
(	I-Material
clumps	I-Material
)	I-Material
was	O
identified	O
as	O
the	O
critical	O
step	O
.	O
	
Cellular	B-Data
morphology	I-Data
,	O
pluripotency	B-Process
gene	I-Process
expression	I-Process
and	O
differentiation	B-Process
into	O
the	B-Material
three	I-Material
germ	I-Material
layers	I-Material
have	O
been	O
used	O
compare	B-Process
the	B-Data
outcomes	I-Data
of	O
manual	B-Process
and	I-Process
automated	I-Process
processes	I-Process
.	O
	
-DOCSTART-	
	
Transplantation	B-Process
of	O
the	B-Material
retinal	I-Material
pigment	I-Material
epithelium	I-Material
(	I-Material
RPE	I-Material
)	I-Material
is	O
being	O
developed	O
as	O
a	B-Process
cell	I-Process
-	I-Process
replacement	I-Process
therapy	I-Process
for	O
age	B-Process
-	I-Process
related	I-Process
macular	I-Process
degeneration	I-Process
.	O
	
Human	B-Material
embryonic	I-Material
stem	I-Material
cell	I-Material
(	I-Material
hESC	I-Material
)	I-Material
and	O
induced	B-Process
pluripotent	B-Material
stem	I-Material
cell	I-Material
	
(	I-Material
iPSC)-derived	I-Material
RPE	I-Material
are	O
currently	O
translating	B-Process
toward	O
clinic	B-Material
.	O
	
We	O
introduce	O
the	B-Material
adult	I-Material
human	I-Material
RPE	I-Material
stem	I-Material
cell	I-Material
(	I-Material
hRPESC	I-Material
)	I-Material
as	O
an	B-Material
alternative	I-Material
RPE	I-Material
source	I-Material
.	O
	
Polarized	B-Material
monolayers	I-Material
of	O
adult	B-Material
hRPESC	I-Material
-	I-Material
derived	I-Material
RPE	I-Material
grown	B-Process
on	O
polyester	B-Material
	
(	I-Material
PET	I-Material
)	I-Material
membranes	I-Material
had	O
near	B-Data
-	I-Data
native	I-Data
characteristics	I-Data
.	O
	
Trephined	B-Material
pieces	I-Material
of	I-Material
RPE	I-Material
monolayers	I-Material
on	O
PET	B-Material
were	O
transplanted	B-Process
subretinally	I-Process
in	O
the	B-Material
rabbit	I-Material
,	I-Material
a	I-Material
large	I-Material
-	I-Material
eyed	I-Material
animal	I-Material
model	I-Material
.	O
	
After	O
4	O
days	O
,	O
retinal	B-Material
edema	I-Material
was	O
observed	O
above	O
the	B-Material
implant	I-Material
,	O
detected	B-Process
by	O
spectral	B-Method
domain	I-Method
optical	I-Method
coherence	I-Method
tomography	I-Method
(	I-Method
SD	I-Method
-	I-Method
OCT	I-Method
)	I-Method
and	I-Method
fundoscopy	I-Method
.	O
	
At	O
1	O
week	O
,	O
retinal	B-Process
atrophy	I-Process
overlying	O
the	B-Material
fetal	I-Material
or	I-Material
adult	I-Material
transplant	I-Material
was	O
observed	O
,	O
remaining	O
stable	B-Data
thereafter	O
.	O
	
Histology	B-Process
obtained	O
4	O
weeks	O
after	O
implantation	B-Process
confirmed	O
a	B-Material
continuous	I-Material
polarized	I-Material
human	I-Material
RPE	I-Material
monolayer	I-Material
on	O
PET	B-Material
.	O
	
Taken	O
together	O
,	O
the	B-Material
xeno	I-Material
-	I-Material
RPE	I-Material
survived	O
with	O
retained	B-Data
characteristics	I-Data
in	O
the	B-Material
subretinal	I-Material
space	I-Material
.	O
	
These	O
experiments	O
support	O
that	O
adult	B-Material
hRPESC	I-Material
-	I-Material
derived	I-Material
RPE	I-Material
are	O
a	O
potential	O
source	O
for	O
transplantation	B-Process
therapies	I-Process
.	O
	
Graphical	O
Abstract	O
Highlights	O
•	O
Adult	B-Material
hRPESC	I-Material
-	I-Material
derived	I-Material
RPE	I-Material
had	O
comparable	O
in	B-Method
vitro	I-Method
characteristics	B-Data
to	O
fetal	B-Material
hRPE	I-Material
•	O
	
hRPE	B-Material
monolayers	I-Material
survived	O
4	O
weeks	O
on	O
PET	B-Material
carriers	I-Material
under	O
the	B-Material
rabbit	I-Material
retina	I-Material
•	O
	
Better	O
xenograft	B-Process
survival	I-Process
may	O
be	O
due	O
to	O
the	B-Data
maintained	I-Data
hRPE	I-Data
cell	I-Data
polarity	I-Data
	
•	O
Atrophy	B-Process
of	O
the	B-Material
retina	I-Material
overlaying	B-Process
the	B-Material
hRPE	I-Material
xenograft	I-Material
remains	O
a	O
future	O
challenge	O
Stanzel	O
et	O
al	O
.	O
	
have	O
transplanted	B-Process
polarized	B-Material
monolayers	I-Material
of	O
human	B-Material
retinal	I-Material
pigment	I-Material
epithelium	I-Material
(	I-Material
hRPE	I-Material
)	I-Material
grown	B-Process
on	O
polyester	B-Material
membranes	I-Material
derived	B-Process
from	O
adult	B-Material
hRPE	I-Material
stem	I-Material
cells	I-Material
or	I-Material
fetal	I-Material
tissue	I-Material
under	O
the	B-Material
rabbit	I-Material
retina	I-Material
.	O
	
The	B-Material
xeno	I-Material
-	I-Material
RPE	I-Material
survived	O
4	O
weeks	O
with	O
retained	O
cell	B-Data
polarity	I-Data
characteristics	I-Data
in	O
the	B-Material
subretinal	I-Material
space	I-Material
.	O
	
These	O
experiments	O
support	O
that	O
adult	B-Material
hRPESC	I-Material
-	I-Material
derived	I-Material
RPE	I-Material
are	O
a	O
potential	O
source	O
for	O
transplantation	B-Process
therapies	I-Process
.	O
	
-DOCSTART-	
	
Large	B-Process
-	I-Process
scale	I-Process
production	I-Process
of	O
human	B-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hiPSCs	I-Material
)	I-Material
by	O
robust	B-Process
and	I-Process
economic	I-Process
methods	I-Process
has	O
been	O
one	O
of	O
the	O
major	O
challenges	O
for	O
translational	B-Process
realization	I-Process
of	O
hiPSC	B-Material
technology	I-Material
.	O
	
Here	O
we	O
demonstrate	B-Process
a	B-Material
scalable	I-Material
culture	I-Material
system	I-Material
for	O
hiPSC	B-Process
expansion	I-Process
using	O
the	B-Material
E8	I-Material
chemically	I-Material
defined	I-Material
and	I-Material
xeno	I-Material
-	I-Material
free	I-Material
medium	I-Material
under	O
either	B-Data
adherent	I-Data
or	I-Data
suspension	I-Data
conditions	I-Data
.	O
	
To	O
optimize	B-Process
suspension	B-Data
conditions	I-Data
guided	O
by	O
a	B-Material
computational	I-Material
simulation	I-Material
,	O
we	O
developed	O
a	O
method	O
to	O
efficiently	B-Process
expand	I-Process
hiPSCs	B-Material
as	O
undifferentiated	B-Material
aggregates	I-Material
in	I-Material
spinner	I-Material
flasks	I-Material
.	O
	
Serial	B-Process
passaging	I-Process
of	O
two	B-Material
different	I-Material
hiPSC	I-Material
lines	I-Material
in	I-Material
the	I-Material
spinner	I-Material
flasks	I-Material
using	O
the	B-Material
E8	I-Material
medium	I-Material
preserved	B-Process
their	B-Data
normal	I-Data
karyotype	I-Data
and	O
expression	B-Process
of	O
undifferentiated	B-Data
state	I-Data
markers	I-Data
of	O
TRA-1	B-Material
-	I-Material
60	I-Material
,	O
SSEA4	B-Material
,	O
OCT4	B-Material
,	O
and	O
NANOG	B-Material
.	O
	
The	B-Material
hiPSCs	I-Material
cultured	B-Process
in	O
spinner	B-Material
flasks	I-Material
for	O
more	O
than	O
10	B-Data
passages	B-Process
not	O
only	O
could	O
be	O
remained	O
pluripotent	B-Process
as	O
indicated	O
by	O
in	B-Material
vitro	I-Material
and	I-Material
in	I-Material
vivo	I-Material
assays	I-Material
,	O
but	O
also	O
could	O
be	O
efficiently	B-Process
induced	I-Process
toward	O
mesodermal	B-Process
and	I-Process
hematopoietic	I-Process
differentiation	I-Process
.	O
	
Furthermore	O
,	O
we	O
established	O
a	B-Method
xeno	I-Method
-	I-Method
free	I-Method
protocol	I-Method
of	O
single	B-Process
-	I-Process
cell	I-Process
cryopreservation	I-Process
and	O
recovery	B-Process
for	O
the	B-Process
scalable	I-Process
production	I-Process
of	O
hiPSCs	B-Material
in	I-Material
spinner	I-Material
flasks	I-Material
.	O
	
This	B-Material
system	I-Material
is	O
the	O
first	O
to	O
enable	O
an	B-Process
efficient	I-Process
scale	I-Process
-	I-Process
up	I-Process
bioprocess	I-Process
in	O
completely	B-Data
xeno	I-Data
-	I-Data
free	I-Data
condition	I-Data
for	O
the	B-Process
expansion	I-Process
and	I-Process
cryopreservation	I-Process
of	O
hiPSCs	B-Material
with	O
the	B-Data
quantity	I-Data
and	I-Data
quality	I-Data
compliant	O
for	O
clinical	B-Process
applications	I-Process
.	O
	
Highlights	O
•	O
	
We	O
report	O
the	B-Material
first	I-Material
suspension	I-Material
culture	I-Material
of	I-Material
hiPSCs	I-Material
using	O
E8	B-Material
medium	I-Material
.	O
	
•	O
	
We	O
report	O
the	B-Material
first	I-Material
hydrodynamic	I-Material
model	I-Material
for	O
glass	B-Material
-	I-Material
ball	I-Material
type	I-Material
spinner	I-Material
flasks	I-Material
.	O
	
•	O
	
We	O
establish	O
a	B-Process
scalable	I-Process
bioprocess	I-Process
in	O
completely	B-Data
defined	I-Data
xeno	I-Data
-	I-Data
free	I-Data
conditions	I-Data
.	O
	
•	O
	
We	O
optimized	B-Process
a	B-Process
single	I-Process
-	I-Process
cell	I-Process
cryopreservation	I-Process
for	O
hiPSCs	B-Material
in	I-Material
suspension	I-Material
.	O
	
•	O
	
Human	B-Material
iPSCs	I-Material
maintained	B-Process
pluripotency	B-Data
and	I-Data
normal	I-Data
karyotype	I-Data
along	O
the	B-Process
bioprocess	I-Process
.	O
	
-DOCSTART-	
	
Familial	B-Process
amyloidotic	I-Process
polyneuropathy	I-Process
(	I-Process
FAP	I-Process
)	I-Process
is	O
a	B-Process
hereditary	I-Process
amyloidosis	I-Process
induced	B-Process
by	O
amyloidogenic	B-Material
transthyretin	I-Material
(	I-Material
ATTR	I-Material
)	I-Material
.	O
	
Because	O
most	B-Material
transthyretin	I-Material
(	I-Material
TTR	I-Material
)	I-Material
in	I-Material
serum	I-Material
is	O
synthesized	B-Process
by	O
the	B-Material
liver	I-Material
,	O
liver	B-Process
transplantation	I-Process
(	I-Process
LT	I-Process
)	I-Process
is	O
today	O
the	O
only	O
treatment	O
available	O
to	O
halt	B-Process
the	B-Process
progression	I-Process
of	I-Process
FAP	I-Process
,	O
even	O
though	O
LT	B-Process
is	O
associated	O
with	O
several	B-Process
problems	I-Process
.	O
	
Despite	O
the	O
urgent	O
need	O
to	O
develop	O
alternatives	O
to	O
LT	B-Process
,	O
the	B-Data
detailed	I-Data
pathogenesis	I-Data
of	O
FAP	B-Process
is	O
still	O
unknown	O
;	O
also	O
,	O
no	O
model	O
fully	O
represents	O
the	B-Process
relevant	I-Process
processes	I-Process
in	O
patients	B-Material
with	O
FAP	B-Process
.	O
	
The	B-Process
induction	I-Process
of	O
induced	B-Material
pluripotent	I-Material
stem	I-Material
(	I-Material
iPS	I-Material
)	I-Material
cells	I-Material
has	O
allowed	O
development	B-Process
of	O
pluripotent	B-Material
cells	I-Material
specific	O
for	O
patients	B-Material
and	O
has	O
led	O
to	O
useful	B-Material
models	I-Material
of	O
human	B-Process
diseases	I-Process
.	O
	
Because	O
of	O
the	O
need	O
for	O
a	O
tool	O
to	O
elucidate	B-Process
the	B-Data
molecular	I-Data
pathogenesis	I-Data
of	O
FAP	B-Process
,	O
in	O
this	O
study	O
we	O
sought	O
to	O
establish	O
heterozygous	B-Material
ATTR	I-Material
mutant	I-Material
iPS	I-Material
cells	I-Material
,	O
and	O
were	O
successful	O
,	O
by	O
using	O
a	B-Material
Sendai	I-Material
virus	I-Material
vector	I-Material
mixture	I-Material
containing	O
four	B-Material
transcription	I-Material
factors	I-Material
(	I-Material
Oct3/4	I-Material
,	I-Material
Sox2	I-Material
,	I-Material
Klf4	I-Material
,	I-Material
and	I-Material
c	I-Material
-	I-Material
Myc	I-Material
)	I-Material
to	O
reprogram	B-Process
dermal	B-Material
fibroblasts	I-Material
derived	B-Process
from	O
FAP	B-Material
patients	I-Material
.	O
	
Moreover	O
,	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
had	O
the	O
potential	O
to	O
differentiate	B-Process
into	O
hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
and	O
indeed	O
expressed	B-Material
ATTR	I-Material
.	O
	
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
demonstrated	O
the	O
possibility	O
of	O
serving	O
as	O
a	B-Method
pathological	I-Method
tool	I-Method
that	O
will	O
contribute	O
to	O
understanding	O
the	B-Data
pathogenesis	I-Data
of	O
FAP	B-Process
and	O
development	O
of	O
FAP	B-Process
treatments	I-Process
.	O
	
Highlights	O
•	O
	
We	O
established	O
,	O
for	O
the	O
first	O
time	O
,	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
by	O
using	O
a	B-Material
Sendai	I-Material
virus	I-Material
.	O
	
•	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
have	O
potential	O
to	O
differentiate	B-Process
into	O
hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
.	O
	
•	O
	
Hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
from	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
indeed	O
expressed	B-Material
ATTR	I-Material
Val30Met	I-Material
.	O
	
•	O
	
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
demonstrate	O
the	O
possibility	O
to	O
serve	O
as	O
a	B-Material
pathological	I-Material
tool	I-Material
.	O
	
-DOCSTART-	
	
The	B-Process
pathogenic	I-Process
mechanisms	I-Process
of	I-Process
frontotemporal	I-Process
dementia	I-Process
(	I-Process
FTD	I-Process
)	I-Process
remain	O
poorly	O
understood	O
.	O
	
Here	O
we	O
generated	B-Process
multiple	B-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cell	I-Material
lines	I-Material
from	O
a	B-Material
control	I-Material
subject	I-Material
,	O
a	B-Material
patient	I-Material
with	O
sporadic	B-Process
FTD	I-Process
,	O
and	O
an	B-Material
FTD	I-Material
patient	I-Material
with	O
a	B-Process
novel	I-Process
heterozygous	I-Process
GRN	I-Process
mutation	I-Process
(	I-Process
progranulin	I-Process
[	I-Process
PGRN	I-Process
]	I-Process
	
S116X	I-Process
)	I-Process
.	O
	
In	O
neurons	B-Material
and	O
microglia	B-Material
differentiated	O
from	O
PGRN	B-Material
S116X	I-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
,	O
the	B-Data
levels	I-Data
of	O
intracellular	B-Material
and	I-Material
secreted	I-Material
PGRN	I-Material
were	O
reduced	O
,	O
establishing	O
patient	B-Material
-	I-Material
specific	I-Material
cellular	I-Material
models	I-Material
of	O
PGRN	B-Process
haploinsufficiency	I-Process
.	O
	
Through	O
a	B-Process
systematic	I-Process
screen	I-Process
of	O
inducers	B-Material
of	O
cellular	B-Process
stress	I-Process
,	O
we	O
found	O
that	O
PGRN	B-Material
S116X	I-Material
neurons	I-Material
,	O
but	O
not	O
sporadic	B-Material
FTD	I-Material
neurons	I-Material
,	O
exhibited	O
increased	B-Data
sensitivity	I-Data
to	O
staurosporine	B-Material
and	O
other	B-Material
kinase	I-Material
inhibitors	I-Material
.	O
	
Moreover	O
,	O
the	B-Material
serine	I-Material
/	I-Material
threonine	I-Material
kinase	I-Material
S6K2	I-Material
,	O
a	O
component	O
of	O
the	B-Material
phosphatidylinositol	I-Material
3-kinase	I-Material
and	I-Material
mitogen	I-Material
-	I-Material
activated	I-Material
protein	I-Material
kinase	I-Material
pathways	I-Material
,	O
was	O
specifically	O
downregulated	B-Process
in	O
PGRN	B-Material
S116X	I-Material
neurons	I-Material
.	O
	
Both	O
increased	B-Data
sensitivity	I-Data
to	O
kinase	B-Material
inhibitors	I-Material
and	O
reduced	B-Material
S6K2	I-Material
were	O
rescued	B-Process
by	O
PGRN	B-Process
expression	I-Process
.	O
	
Our	O
findings	O
identify	O
cell	B-Data
-	I-Data
autonomous	I-Data
,	I-Data
reversible	I-Data
defects	I-Data
in	O
patient	B-Material
neurons	I-Material
with	O
PGRN	B-Data
deficiency	I-Data
,	O
and	O
provide	O
a	O
compelling	O
model	O
for	O
studying	B-Process
PGRN	B-Process
-	I-Process
dependent	I-Process
pathogenic	I-Process
mechanisms	I-Process
and	O
testing	B-Process
potential	B-Process
therapies	I-Process
.	O
	
Graphical	O
Abstract	O
Highlights	O
	
►	O
	
A	B-Method
human	I-Method
neuron	I-Method
model	I-Method
of	O
progranulin	B-Process
(	I-Process
PGRN	I-Process
)	I-Process
haploinsufficiency	I-Process
is	O
established	O
►	O
	
Sporadic	B-Material
and	I-Material
PGRN	I-Material
-	I-Material
deficient	I-Material
frontotemporal	I-Material
dementia	I-Material
patient	I-Material
iPSCs	B-Material
are	O
made	O
►	O
	
PGRN	B-Material
S116X	I-Material
mutant	I-Material
neurons	I-Material
are	O
sensitive	O
to	O
stress	B-Process
by	O
kinase	B-Material
inhibitors	I-Material
	
►	O
	
S6K2	B-Material
is	O
downregulated	B-Process
in	O
patient	B-Material
neurons	I-Material
in	O
a	B-Process
PGRN	I-Process
-	I-Process
dependent	I-Process
manner	I-Process
Progranulin	B-Process
(	I-Process
PGRN	I-Process
)	I-Process
mutations	I-Process
are	O
a	O
common	O
cause	O
of	O
frontotemporal	B-Process
dementia	I-Process
,	O
but	O
the	B-Process
underlying	I-Process
molecular	I-Process
mechanism	I-Process
is	O
unknown	O
.	O
	
Gao	O
and	O
colleagues	O
now	O
generate	O
multiple	B-Material
frontotemporal	I-Material
dementia	I-Material
patient	I-Material
-	I-Material
specific	I-Material
induced	I-Material
pluripotent	I-Material
stem	I-Material
cell	I-Material
lines	I-Material
and	O
establish	O
a	B-Method
human	I-Method
neuronal	I-Method
model	I-Method
of	O
PGRN	B-Process
haploinsufficiency	I-Process
.	O
	
Studies	O
on	O
human	B-Material
postmitotic	I-Material
neurons	I-Material
derived	O
from	O
these	B-Material
lines	I-Material
reveal	O
cell	B-Process
-	I-Process
autonomous	I-Process
and	I-Process
reversible	I-Process
defects	I-Process
in	O
specific	B-Material
signaling	I-Material
pathways	I-Material
that	O
are	O
compromised	O
in	O
PGRN	B-Material
-	I-Material
deficient	I-Material
neurons	I-Material
and	O
establish	O
a	B-Material
model	I-Material
system	I-Material
for	O
studying	B-Process
PGRN	B-Process
-	I-Process
dependent	I-Process
pathogenic	I-Process
mechanisms	I-Process
and	O
testing	B-Process
potential	B-Process
therapies	I-Process
.	O
	
-DOCSTART-	
	
Cranial	B-Material
placodes	I-Material
are	O
embryonic	B-Material
structures	I-Material
essential	O
for	O
sensory	B-Process
and	I-Process
endocrine	I-Process
organ	I-Process
development	I-Process
.	O
	
Human	B-Process
placode	I-Process
development	I-Process
has	O
remained	O
largely	O
inaccessible	O
despite	O
the	B-Data
serious	I-Data
medical	I-Data
conditions	I-Data
caused	O
by	O
the	B-Process
dysfunction	I-Process
of	O
placode	B-Material
-	I-Material
derived	I-Material
tissues	I-Material
.	O
	
Here	O
,	O
we	O
demonstrate	O
the	B-Process
efficient	I-Process
derivation	I-Process
of	O
cranial	B-Material
placodes	I-Material
from	O
human	B-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
.	O
	
Timed	B-Process
removal	I-Process
of	O
the	B-Material
BMP	I-Material
inhibitor	I-Material
Noggin	I-Material
,	O
a	O
component	O
of	O
the	B-Method
dual	I-Method
-	I-Method
SMAD	I-Method
inhibition	I-Method
strategy	I-Method
of	O
neural	B-Process
induction	I-Process
,	O
triggers	B-Process
placode	B-Process
induction	I-Process
at	O
the	O
expense	O
of	O
CNS	B-Data
fates	I-Data
.	O
	
Concomitant	B-Process
inhibition	I-Process
of	O
fibroblast	B-Process
growth	I-Process
factor	I-Process
signaling	I-Process
disrupts	B-Process
placode	B-Process
derivation	I-Process
and	O
induces	B-Process
surface	B-Material
ectoderm	I-Material
.	O
	
Further	O
fate	B-Data
specification	I-Data
at	O
the	B-Data
preplacode	I-Data
stage	I-Data
enables	O
the	B-Process
selective	I-Process
generation	I-Process
of	O
placode	B-Material
-	I-Material
derived	I-Material
trigeminal	I-Material
ganglia	I-Material
capable	O
of	O
in	B-Method
vivo	I-Method
engraftment	B-Process
,	O
mature	B-Material
lens	I-Material
fibers	I-Material
,	O
and	O
anterior	B-Material
pituitary	I-Material
hormone	I-Material
-	I-Material
producing	I-Material
cells	I-Material
that	O
upon	O
transplantation	B-Process
produce	O
human	B-Material
growth	I-Material
hormone	I-Material
and	O
adrenocorticotropic	B-Material
hormone	I-Material
in	B-Method
vivo	I-Method
.	O
	
Our	O
results	O
establish	O
a	B-Material
powerful	I-Material
experimental	I-Material
platform	I-Material
to	O
study	O
human	B-Process
cranial	I-Process
placode	I-Process
development	I-Process
and	O
set	O
the	O
stage	O
for	O
the	B-Process
development	I-Process
of	O
human	B-Process
cell	I-Process
-	I-Process
based	I-Process
therapies	I-Process
in	O
sensory	B-Process
and	I-Process
endocrine	I-Process
disease	I-Process
.	O
	
Graphical	O
Abstract	O
Highlights	O
•	O
Timed	B-Process
withdrawal	I-Process
of	O
BMP	B-Material
inhibitor	I-Material
is	O
sufficient	O
to	O
induce	B-Process
placode	B-Data
fates	I-Data
from	O
hESCs	B-Material
•	O
Timed	B-Process
FGF	I-Process
inhibition	I-Process
suppresses	B-Process
placode	B-Data
fate	I-Data
and	O
induces	B-Process
epidermal	B-Material
lineage	I-Material
•	O
Placode	B-Material
-	I-Material
derived	I-Material
trigeminal	I-Material
neurons	I-Material
are	O
functional	B-Process
in	B-Method
vitro	I-Method
and	O
engraft	B-Process
in	B-Method
vivo	I-Method
•	O
Pituitary	B-Material
placode	I-Material
-	I-Material
derived	I-Material
cells	I-Material
are	O
capable	O
of	O
hormone	B-Process
release	I-Process
in	B-Method
vitro	I-Method
and	I-Method
in	I-Method
vivo	I-Method
	
Cranial	B-Material
placodes	I-Material
are	O
essential	O
for	O
the	B-Process
development	I-Process
of	O
sensory	B-Material
and	I-Material
endocrine	I-Material
organs	I-Material
.	O
	
Here	O
,	O
Studer	O
and	O
colleagues	O
report	O
the	B-Process
efficient	I-Process
derivation	I-Process
of	O
cranial	B-Material
placodes	I-Material
from	O
human	B-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
.	O
	
They	O
demonstrate	O
how	O
to	O
obtain	O
specific	B-Material
placode	I-Material
derivatives	I-Material
such	O
as	O
trigeminal	B-Material
ganglia	I-Material
capable	O
of	O
in	B-Method
vivo	I-Method
engraftment	B-Process
,	O
mature	B-Material
lens	I-Material
fibers	I-Material
,	O
and	O
anterior	B-Material
pituitary	I-Material
cells	I-Material
capable	O
of	O
producing	B-Process
human	B-Material
GH	I-Material
and	I-Material
ACTH	I-Material
in	B-Method
vivo	I-Method
.	O
	
Their	O
results	O
establish	O
a	B-Material
platform	I-Material
for	O
studying	B-Process
human	B-Process
cranial	I-Process
placode	I-Process
development	I-Process
and	O
for	O
applications	B-Process
of	O
placode	B-Material
derivatives	I-Material
in	O
regenerative	B-Process
medicine	I-Process
.	O
	
-DOCSTART-	
	
Tauopathies	B-Process
represent	O
a	B-Process
group	I-Process
of	I-Process
neurodegenerative	I-Process
disorders	I-Process
characterized	O
by	O
the	B-Process
accumulation	I-Process
of	O
pathological	B-Material
TAU	I-Material
protein	I-Material
in	O
brains	B-Material
.	O
	
We	O
report	O
a	B-Material
human	I-Material
neuronal	I-Material
model	I-Material
of	O
tauopathy	B-Process
derived	B-Process
from	O
induced	B-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
iPSCs	I-Material
)	I-Material
carrying	O
a	B-Process
TAU	I-Process
-	I-Process
A152	I-Process
T	I-Process
mutation	I-Process
.	O
	
Using	O
zinc	B-Process
-	I-Process
finger	I-Process
nuclease	I-Process
-	I-Process
mediated	I-Process
gene	I-Process
editing	I-Process
,	O
we	O
generated	B-Process
two	B-Material
isogenic	I-Material
iPSC	I-Material
lines	I-Material
:	O
one	O
with	O
the	B-Process
mutation	I-Process
corrected	B-Process
,	O
and	O
another	O
with	O
the	B-Process
homozygous	I-Process
mutation	I-Process
engineered	B-Process
.	O
	
The	B-Process
A152	I-Process
T	I-Process
mutation	I-Process
increased	B-Process
TAU	B-Process
fragmentation	I-Process
and	I-Process
phosphorylation	I-Process
,	O
leading	O
to	O
neurodegeneration	B-Process
and	O
especially	O
axonal	B-Process
degeneration	I-Process
.	O
	
These	B-Data
cellular	I-Data
phenotypes	I-Data
were	O
consistent	O
with	O
those	O
observed	O
in	O
a	B-Material
patient	I-Material
with	O
	
TAU	B-Material
-	I-Material
A152T.	I-Material
Upon	O
mutation	B-Process
correction	I-Process
,	O
normal	B-Data
neuronal	I-Data
and	I-Data
axonal	I-Data
morphologies	I-Data
were	O
restored	B-Process
,	O
accompanied	O
by	O
decreases	B-Process
in	O
TAU	B-Process
fragmentation	I-Process
and	I-Process
phosphorylation	I-Process
,	O
whereas	O
the	B-Data
severity	I-Data
of	O
tauopathy	B-Process
was	O
intensified	B-Process
in	O
neurons	B-Material
with	O
the	B-Process
homozygous	I-Process
mutation	I-Process
.	O
	
These	B-Material
isogenic	I-Material
TAU	I-Material
-	I-Material
iPSC	I-Material
lines	I-Material
represent	O
a	O
critical	O
advancement	O
toward	O
the	B-Process
accurate	I-Process
modeling	I-Process
and	O
mechanistic	B-Process
study	I-Process
of	O
tauopathies	B-Process
with	O
human	B-Material
neurons	I-Material
and	O
will	O
be	O
invaluable	O
for	O
drug	B-Process
-	I-Process
screening	I-Process
efforts	I-Process
and	O
future	O
cell	B-Process
-	I-Process
based	I-Process
therapies	I-Process
.	O
	
Highlights	O
•	O
	
A	B-Material
human	I-Material
neuron	I-Material
model	I-Material
of	O
tauopathy	B-Process
using	O
TAU	B-Material
-	I-Material
A152T	I-Material
-	I-Material
iPSCs	I-Material
•	O
Correction	B-Process
of	O
TAU	B-Process
-	I-Process
A152	I-Process
T	I-Process
mutation	I-Process
eliminates	B-Process
tauopathy	B-Process
•	O
Engineered	B-Process
homozygous	B-Process
TAU	I-Process
-	I-Process
A152	I-Process
T	I-Process
mutation	I-Process
intensifies	B-Process
tauopathy	B-Process
•	O
A152	B-Process
T	I-Process
mutation	I-Process
increases	B-Process
TAU	B-Process
proteolysis	I-Process
,	O
leading	O
to	O
tauopathy	B-Process
	
-DOCSTART-	
	
Induced	B-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
iPSCs	I-Material
)	I-Material
provide	O
the	O
potential	O
for	O
autologous	B-Process
transplantation	I-Process
using	O
cells	B-Material
derived	B-Process
from	O
a	B-Material
patient	I-Material
's	I-Material
own	I-Material
cells	I-Material
.	O
	
However	O
,	O
the	B-Process
immunogenicity	I-Process
of	O
iPSCs	B-Material
or	O
their	B-Material
derivatives	I-Material
has	O
been	O
a	O
matter	O
of	O
controversy	O
,	O
and	O
up	O
to	O
now	O
there	O
has	O
been	O
no	O
direct	B-Process
comparison	I-Process
of	O
autologous	B-Process
and	I-Process
allogeneic	I-Process
transplantation	I-Process
in	O
the	B-Material
brains	I-Material
of	I-Material
humans	I-Material
or	I-Material
nonhuman	I-Material
primates	I-Material
.	O
	
Here	O
,	O
using	O
nonhuman	B-Material
primates	I-Material
,	O
we	O
found	O
that	O
the	B-Process
autologous	I-Process
transplantation	I-Process
of	O
iPSC	B-Material
-	I-Material
derived	I-Material
neurons	I-Material
elicited	O
only	O
a	B-Process
minimal	I-Process
immune	I-Process
response	I-Process
in	O
the	B-Material
brain	I-Material
.	O
	
In	O
contrast	O
,	O
the	B-Material
allografts	I-Material
caused	O
an	B-Process
acquired	I-Process
immune	I-Process
response	I-Process
with	O
the	B-Process
activation	I-Process
of	O
microglia	B-Material
(	I-Material
IBA-1+/MHC	I-Material
class	I-Material
II+	I-Material
)	I-Material
and	O
the	B-Process
infiltration	I-Process
of	O
leukocytes	B-Material
(	I-Material
CD45+/CD3	I-Material
+	I-Material
)	I-Material
.	O
	
Consequently	O
,	O
a	B-Data
higher	I-Data
number	I-Data
of	O
dopaminergic	B-Material
neurons	I-Material
survived	B-Process
in	O
the	B-Material
autografts	I-Material
.	O
	
Our	O
results	O
suggest	O
that	O
the	B-Process
autologous	I-Process
transplantation	I-Process
of	O
iPSC	B-Material
-	I-Material
derived	I-Material
neural	I-Material
cells	I-Material
is	O
advantageous	O
for	O
minimizing	B-Process
the	B-Process
immune	I-Process
response	I-Process
in	O
the	B-Material
brain	I-Material
compared	O
with	O
allogeneic	B-Material
grafts	I-Material
.	O
	
Graphical	O
Abstract	O
Highlights	O
•	O
iPSC	B-Material
-	I-Material
derived	I-Material
autografts	I-Material
cause	O
only	O
a	B-Process
minimal	I-Process
immune	I-Process
response	I-Process
in	O
the	B-Material
primate	I-Material
brain	I-Material
•	O
	
Autografts	B-Material
have	O
advantages	O
over	O
allografts	B-Material
even	O
at	O
an	B-Material
immune	I-Material
-	I-Material
privileged	I-Material
site	I-Material
•	O
	
Dopamine	B-Material
neurons	I-Material
survive	B-Process
even	O
in	O
allografts	B-Material
without	O
immunosuppression	B-Process
	
The	B-Process
autologous	I-Process
transplantation	I-Process
of	O
iPSC	B-Material
-	I-Material
derived	I-Material
neurons	I-Material
elicited	O
only	O
a	B-Process
minimal	I-Process
immune	I-Process
response	I-Process
in	O
the	B-Material
brain	I-Material
.	O
	
In	O
contrast	O
,	O
the	B-Material
allografts	I-Material
caused	O
an	B-Process
acquired	I-Process
immune	I-Process
response	I-Process
with	O
the	B-Process
activation	I-Process
of	O
microglia	B-Material
(	I-Material
IBA-1+/MHC	I-Material
class	I-Material
II+	I-Material
)	I-Material
and	O
the	B-Process
infiltration	I-Process
of	O
leukocytes	B-Material
(	I-Material
CD45+/CD3	I-Material
+	I-Material
)	I-Material
.	O
	
Autologous	B-Process
transplantation	I-Process
is	O
advantageous	O
for	O
minimizing	B-Process
the	B-Process
immune	I-Process
response	I-Process
compared	O
with	O
allogeneic	B-Material
grafts	I-Material
.	O
	
-DOCSTART-	
	
Human	B-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hPSCs	I-Material
)	I-Material
could	O
provide	O
an	B-Process
infinite	I-Process
source	I-Process
of	O
clinically	B-Material
relevant	I-Material
cells	I-Material
with	O
potential	O
applications	O
in	O
regenerative	B-Process
medicine	I-Process
.	O
	
However	O
,	O
hPSC	B-Material
lines	I-Material
vary	O
in	O
their	O
capacity	O
to	O
generate	B-Process
specialized	B-Material
cells	I-Material
,	O
and	O
the	B-Process
development	I-Process
of	O
universal	B-Process
protocols	I-Process
for	O
the	B-Process
production	I-Process
of	O
tissue	B-Material
-	I-Material
specific	I-Material
cells	I-Material
remains	O
a	O
major	O
challenge	O
.	O
	
Here	O
,	O
we	O
have	O
addressed	O
this	O
limitation	O
for	O
the	B-Material
endodermal	I-Material
lineage	I-Material
by	O
developing	B-Process
a	B-Material
defined	I-Material
culture	I-Material
system	I-Material
to	O
expand	B-Process
and	O
differentiate	B-Process
human	B-Material
foregut	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hFSCs	I-Material
)	I-Material
derived	B-Process
from	O
hPSCs	B-Material
.	O
	
hFSCs	B-Material
can	O
self	B-Process
-	I-Process
renew	I-Process
while	O
maintaining	B-Process
their	B-Data
capacity	I-Data
to	O
differentiate	B-Process
into	O
pancreatic	B-Material
and	I-Material
hepatic	I-Material
cells	I-Material
.	O
	
Furthermore	O
,	O
near	B-Material
-	I-Material
homogenous	I-Material
populations	I-Material
of	I-Material
hFSCs	I-Material
can	O
be	O
obtained	O
from	O
hPSC	B-Material
lines	I-Material
which	O
are	O
normally	O
refractory	B-Process
to	I-Process
endodermal	I-Process
differentiation	I-Process
.	O
	
Therefore	O
,	O
hFSCs	B-Material
provide	O
a	O
unique	O
approach	O
to	O
bypass	B-Process
variability	B-Process
between	O
pluripotent	B-Material
lines	I-Material
in	O
order	O
to	O
obtain	O
a	B-Material
sustainable	I-Material
source	I-Material
of	I-Material
multipotent	I-Material
endoderm	I-Material
stem	I-Material
cells	I-Material
for	O
basic	O
studies	O
and	O
to	O
produce	B-Process
a	B-Material
diversity	I-Material
of	I-Material
endodermal	I-Material
derivatives	I-Material
with	O
a	B-Data
clinical	I-Data
value	I-Data
.	O
	
Highlights	O
•	O
	
Multipotent	B-Material
foregut	I-Material
stem	I-Material
cells	I-Material
are	O
derived	B-Process
from	O
pluripotent	B-Material
cells	I-Material
•	O
Foregut	B-Material
stem	I-Material
cells	I-Material
can	O
be	O
expanded	B-Process
and	O
retain	B-Process
their	B-Data
differentiation	I-Data
potential	I-Data
•	O
Foregut	B-Material
stem	I-Material
cells	I-Material
differentiate	B-Process
into	O
liver	B-Material
and	I-Material
pancreatic	I-Material
cells	I-Material
•	O
Foregut	B-Material
stem	I-Material
cells	I-Material
decrease	B-Process
differentiation	B-Process
variability	I-Process
between	O
cell	B-Material
lines	I-Material
Hannan	O
,	O
Vallier	O
,	O
and	O
colleagues	O
have	O
developed	B-Process
a	B-Material
defined	I-Material
culture	I-Material
system	I-Material
to	O
differentiate	B-Process
and	O
expand	B-Process
human	B-Material
foregut	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hFSCs	I-Material
)	I-Material
from	O
human	B-Material
pluripotent	I-Material
cells	I-Material
.	O
	
hFSCs	B-Material
can	O
self	B-Process
-	I-Process
renew	I-Process
while	O
maintaining	B-Process
their	B-Data
capacity	I-Data
to	O
differentiate	O
into	O
pancreatic	B-Material
and	I-Material
hepatic	I-Material
cells	I-Material
.	O
	
hFSCs	B-Material
represent	O
a	B-Process
sustainable	I-Process
source	I-Process
of	O
multipotent	B-Material
endodermal	I-Material
cells	I-Material
for	O
basic	O
studies	O
and	O
can	O
produce	B-Process
a	B-Material
diversity	I-Material
of	I-Material
endodermal	I-Material
derivatives	I-Material
with	O
clinical	B-Data
value	I-Data
.	O
	
-DOCSTART-	
	
SOX2	B-Material
is	O
involved	O
in	O
several	B-Process
cell	I-Process
and	I-Process
developmental	I-Process
processes	I-Process
,	O
including	O
maintenance	B-Process
of	O
embryonic	B-Material
stem	I-Material
cells	I-Material
,	O
differentiation	B-Process
of	O
neural	B-Material
progenitor	I-Material
cells	I-Material
,	O
and	O
patterning	B-Process
of	O
gut	B-Material
endoderm	I-Material
.	O
	
To	O
study	O
its	O
role	O
in	O
a	B-Material
human	I-Material
system	I-Material
,	O
we	O
generated	B-Process
a	B-Material
human	I-Material
embryonic	I-Material
stem	I-Material
cell	I-Material
(	I-Material
hESC	I-Material
)	I-Material
line	I-Material
harboring	B-Process
a	B-Material
reporter	I-Material
gene	I-Material
encoding	I-Material
GFP	I-Material
in	O
the	B-Material
SOX2	I-Material
locus	I-Material
.	O
	
This	B-Material
SOX2	I-Material
reporter	I-Material
line	I-Material
faithfully	O
recapitulates	O
expression	B-Process
of	O
the	B-Material
SOX2	I-Material
gene	I-Material
in	O
undifferentiated	B-Material
human	I-Material
pluripotent	I-Material
stem	I-Material
cells	I-Material
(	I-Material
hPSCs	I-Material
)	I-Material
,	I-Material
neural	I-Material
progenitor	I-Material
cells	I-Material
(	I-Material
NPCs	I-Material
)	I-Material
,	I-Material
and	I-Material
anterior	I-Material
foregut	I-Material
endoderm	I-Material
(	I-Material
AFE	I-Material
)	I-Material
.	O
	
In	O
undifferentiated	B-Material
hESCs	I-Material
,	O
GFP	B-Process
expression	I-Process
corresponds	O
to	O
those	B-Material
cells	I-Material
with	O
highest	B-Data
levels	I-Data
of	O
expression	B-Process
of	I-Process
genes	I-Process
associated	O
with	O
the	B-Data
pluripotent	I-Data
state	I-Data
.	O
	
In	O
NPCs	B-Material
,	O
expression	B-Process
of	O
GFP	B-Material
can	O
be	O
employed	O
to	O
isolate	B-Process
cells	B-Data
expressing	I-Data
markers	I-Data
associated	O
with	O
NPC	B-Process
multipotency	I-Process
.	O
	
In	O
AFE	B-Material
,	O
we	O
used	O
transcriptome	B-Process
-	I-Process
wide	I-Process
expression	I-Process
analysis	I-Process
to	O
identify	O
cell	B-Data
surface	I-Data
markers	I-Data
with	O
elevated	B-Process
expression	I-Process
in	O
this	B-Material
population	I-Material
,	O
thereby	O
facilitating	O
isolation	B-Process
and	O
purification	B-Process
of	O
this	B-Material
hPSC	I-Material
-	I-Material
derived	I-Material
cell	I-Material
population	I-Material
.	O
	
Highlights	O
	
A	B-Material
SOX2-GFP	I-Material
hESC	I-Material
line	I-Material
is	O
used	O
to	O
isolate	B-Process
and	O
characterize	B-Process
multiple	B-Material
cell	I-Material
types	I-Material
A	B-Data
cell	I-Data
surface	I-Data
marker	I-Data
signature	I-Data
allows	O
for	O
the	B-Process
purification	I-Process
of	O
endodermal	B-Material
progeny	I-Material
Targeted	B-Process
gene	I-Process
insertion	I-Process
with	O
adeno	B-Material
-	I-Material
associated	I-Material
virus	I-Material
(	I-Material
AAV	I-Material
)	I-Material
is	O
highly	O
efficient	O
SOX2	B-Material
is	O
expressed	O
during	O
multiple	B-Process
developmental	I-Process
stages	I-Process
.	O
	
Brafman	O
,	O
Willert	O
,	O
and	O
colleagues	O
used	O
human	B-Material
embryonic	I-Material
stem	I-Material
cells	I-Material
carrying	O
a	B-Material
SOX2	I-Material
reporter	I-Material
to	O
characterize	O
its	B-Process
expression	I-Process
in	O
undifferentiated	B-Material
cells	I-Material
and	O
in	O
neural	B-Material
and	I-Material
lung	I-Material
progenitor	I-Material
cells	I-Material
.	O
	
This	O
approach	O
led	O
to	O
the	B-Process
identification	I-Process
of	O
a	B-Data
cell	I-Data
surface	I-Data
signature	I-Data
to	O
isolate	B-Process
prospective	O
lung	B-Material
progenitors	I-Material
.	O
	
